Loading...
XNASSEEL
Market cap226kUSD
Nov 18, Last price  
0.39USD
Name

Seelos Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:SEEL chart
P/E
—
P/S
0.10
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
116.63%
Rev. gr., 5y
-71.98%
Revenues
2m
359,3692,399,1611,866,9271,270,3675,957,4912,973,7084,972,7374,101,1248,416,0002,511,0009,259,0004,839,0005,763,00000375,0000002,203,000
Net income
-38m
L-50.25%
-17,023,648-15,442,438-8,043,253-8,787,228-5,171,198-32,042,562-29,508,346-18,117,198-31,771,000-16,938,000-21,786,000-19,023,000-7,433,000321,000-9,242,000-50,383,000-19,220,000-67,533,000-76,138,000-37,882,000
CFO
-24m
L-61.18%
-15,227,782-9,835,721-6,667,014-6,587,633-2,712,451-3,514,649-6,889,033-9,724,898-14,395,000-15,065,000-18,015,000-22,642,000-13,068,000-10,466,000-8,129,000-19,305,000-20,913,000-48,995,000-61,604,000-23,912,000
Earnings
Mar 04, 2025

Profile

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
URL
https://seelostherapeutics.com/
IPO date
Oct 27, 1993
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,203
 
Cost of revenue
72,762
70,969
61,669
Unusual Expense (Income)
NOPBT
(70,559)
(70,969)
(61,669)
NOPBT Margin
Operating Taxes
2,604
1,485
Tax Rate
NOPAT
(70,559)
(73,573)
(63,154)
Net income
(37,882)
-50.25%
(76,138)
12.74%
(67,533)
251.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,919
1,486
118,160
BB yield
-17.36%
-0.13%
-4.98%
Debt
Debt current
14,228
11,923
1,068
Long-term debt
15
8,272
17,928
Deferred revenue
Other long-term liabilities
(17,890)
Net debt
11,247
4,662
(59,738)
Cash flow
Cash from operating activities
(23,912)
(61,604)
(48,995)
CAPEX
Cash from investing activities
Cash from financing activities
11,375
(1,597)
112,067
FCF
(51,205)
(73,606)
(63,193)
Balance
Cash
2,996
15,533
78,734
Long term investments
Excess cash
2,886
15,533
78,734
Stockholders' equity
(252,616)
(214,637)
(141,105)
Invested Capital
233,334
224,148
217,386
ROIC
ROCE
365.93%
EV
Common stock shares outstanding
4,900
3,545
3,030
Price
22.24
-93.18%
325.92
-58.34%
782.40
3.16%
Market cap
108,981
-90.57%
1,155,301
-51.26%
2,370,412
109.46%
EV
120,228
1,159,963
2,310,674
EBITDA
(70,502)
(70,916)
(60,087)
EV/EBITDA
Interest
75
14
1,598
Interest/NOPBT